Management Guidance
In the Q2â2025 press release, 60âŻDegrees Pharmaceuticals did not disclose quantitative revenue or earnings guidance for either the upcoming thirdâquarter or the fullâyear 2025. The only forwardâlooking commentary from management was a qualitative statement that the companyâs $1.97âŻmillion cash balance, bolstered by the recent cashâpay sales surge, is expected to carry the business through to MarchâŻ2026, giving it roughly a 12âmonth operating runway. No specific Q3 topâline or fullâyear revenue, EBITDA, or netâincome targets were provided.
Trading Implications
Because explicit guidance is missing, the stock will likely trade on a âguidanceâfreeâ narrative: investors will focus on the operational runway, the recent supplyâchain constraint that trimmed Q2 revenue, and the upside potential from cashâpay sales. In the short term, the lack of a concrete outlook may keep volatility elevated as market participants priceâin their own Q3/2025 earnings expectations. Technical traders might watch the price action around the current support level (often near the 200âday moving average) for a breakoutâeither a bounce if the market interprets the extended cash runway as a defensive moat, or a breakdown if traders demand a more defined earnings roadmap. Until management releases a formal Q3/fullâyear outlook, a cautious stance (e.g., smallâposition sizing or a waitâforâguidance trade) is prudent.